サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がん領域バイオシミラー市場：薬剤クラス別、がんタイプ別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測
市場調査レポート
商品コード
1339905

がん領域バイオシミラー市場：薬剤クラス別、がんタイプ別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測

Oncology Biosimilars Market with COVID-19 Impact Analysis, By Drug Class, By Type of Cancer, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 302 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
がん領域バイオシミラー市場：薬剤クラス別、がんタイプ別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2023年08月01日
発行: AnalystView Market Insights
ページ情報: 英文 302 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

オンコロジーバイオシミラーの市場規模は2022年に42億12万米ドルとなり、2023年から2030年にかけてCAGR 10.67%で拡大

がん領域バイオシミラー市場-市場力学：

  • がんの有病率の増加。
  • がんの罹患率の上昇が、がん領域のバイオシミラー市場を牽引する主な要因です。国際がん研究機関（IARC）は、2040年までに世界で1,630万人のがん関連死が発生し、2,750万人が新たにがんと診断されると予測しています。正常な細胞は、通常、前がん病変から、がんが始まると悪性腫瘍となる多段階のプロセスを経る。加齢者は、通常のリスクの蓄積に加え、細胞の修復システムの効果が低下していることが多いです。喫煙、飲酒、粗食、不摂生な生活、大気汚染はすべて、がん発症の可能性を高める。

オンコロジー・バイオシミラー市場-セグメンテーション分析：

  • 世界のがん領域バイオシミラー市場は、薬剤クラス別、がんの種類別、流通チャネル別、地域別に区分されます。
  • 薬剤クラス別では、モノクローナル抗体、G-CSF、造血剤、その他に分類されます。G-CSFの市場シェアが高いのは、がん治療後の白血球の回復を助けるために化学療法後にG-CSFが広く使用されている結果です。顆粒球コロニー刺激因子（G-CSF）には、フィルグラスチム、レノグラスチム、長時間作用型フィルグラスチム、ペグフィルグラスチムなど、さまざまな形態があります。
  • 乳がん、肺がん、胃がん、前立腺がん、子宮頸がん、血液がん、脳腫瘍、その他。すべての悪性腫瘍の中で乳がん患者の割合が世界的に最も高いため、乳がん分野が市場を独占しています。乳がんのリスクは、年齢、肥満、アルコール依存症、タバコの使用、閉経後のホルモン治療、放射線被曝歴、家族歴など、多くの変数によって増加します。

がん領域バイオシミラー市場-地理的洞察：

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスを展開する国によってさらに分けられます。アジア太平洋地域は新興国市場であり、特に韓国、中国、インドががんバイオシミラーで躍進しています。人口の多さ、健康志向の高まり、医療費の増加、製造コストの低下により、市場の将来性も反映されています。

がん領域のバイオシミラー市場-競合情勢：

各社は、企業サイト、eコマースサイト、小売業者、流通業者、最終消費者など、さまざまなチャネルを通じて製品を販売しています。製品メーカーは、製品のコスト、性能、製品の製造、流通チャネル、評判、入手可能性など、さまざまな側面で競争しています。リーチを強化し市場シェアを拡大するために企業が用いる主な手法には、新製品の発売、流通網の開拓、研究開発費、M&Aなどがあります。例えば、2022年5月、Biocon BiologicsとViatrisが製造する第3のがんバイオシミラーであるAbevmy（ベバシズマブ）がカナダで入手可能になっています。

目次

第1章 腫瘍学バイオシミラー市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 腫瘍学バイオシミラーの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 腫瘍学バイオシミラー業界の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 腫瘍学バイオシミラー市場：COVID-19症の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 腫瘍学バイオシミラー市場情勢

  • 腫瘍学バイオシミラー市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 腫瘍学バイオシミラー市場-薬剤クラス別

  • 概要
    • 薬剤クラス別のセグメントシェア分析
    • モノクローナル抗体
    • G-CSF
    • 造血剤
    • その他

第8章 腫瘍学バイオシミラー市場- がんの種類別

  • 概要
    • がんの種類別セグメントシェア分析
    • 乳がん
    • 肺がん
    • 胃がん
    • 前立腺がん
    • 子宮頸がん
    • 血液がん
    • 脳腫瘍
    • その他

第9章 腫瘍学バイオシミラー市場- 流通チャネル別

  • 概要
    • 販売チャネル別のセグメントシェア分析
    • 小売薬局
    • 病院薬局
    • オンライン薬局

第10章 腫瘍学バイオシミラー市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 腫瘍学バイオシミラー業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Teva Pharmaceuticals
    • STADA Arzneimittel AG
    • Shanghai Henlius Biotech
    • Sandoz（Novartis）
    • Samsung Bioepis
    • Pfizer
    • Pfenex Inc.
    • Mylan
    • Innovent Biologics
    • Dr. Reddy's Laboratories
    • Celltrion Healthcare
    • Biocon
    • Apotex
    • Amgen
    • Accord Healthcare

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Oncology Biosimilars Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Oncology Biosimilars Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Type of Cancer Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type of Cancer
  • TABLE Global Oncology Biosimilars Market, by Type of Cancer 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Oncology Biosimilars Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Oncology Biosimilars Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Oncology Biosimilars Market, by Region 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE North America Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Europe Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Asia Pacific Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Latin America Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Type of Cancer, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Oncology Biosimilars Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Oncology Biosimilars Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022 & 2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Type of Cancer segment market share analysis, 2022 & 2030
  • FIGURE Type of Cancer segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022 & 2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Europe Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Asia Pacific Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Latin America Oncology Biosimilars Market share and leading players, 2022
  • FIGURE Middle East and Africa Oncology Biosimilars Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Germany Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE India Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Brazil Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Oncology Biosimilars Market share analysis by country, 2022
  • FIGURE Saudi Arabia Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Oncology Biosimilars Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1629

REPORT HIGHLIGHT

Oncology Biosimilars Market size was valued at USD 4,200.12 Million in 2022, expanding at a CAGR of 10.67% from 2023 to 2030.

Oncology biosimilars are biological medicines created to be strikingly comparable to and functionally equal to the oncology reference biologics, which are currently available in pharmaceuticals. These biosimilars are created to offer affordable cancer therapy choices. They go through thorough comparative tests to show that they are comparable in terms of safety, quality, and efficacy. Oncology biosimilars seek to improve patient access to essential cancer treatments while also perhaps lowering healthcare costs by providing therapeutic results that are equivalent to those of the unique oncology biologics. A comprehensive regulatory review is required for their approval to guarantee patient safety and maintain cancer treatment requirements.

Oncology Biosimilars Market- Market Dynamics:

  • Increasing prevalence of cancer.
  • The rising incidence of cancer is the primary factor driving the market for oncology biosimilars. The International Agency for Research on Cancer (IARC) predicts that by 2040, there would be 16.3 million cancer-related deaths globally and 27.5 million new cancer diagnoses. Normal cells go through a multi-stage process that normally goes from a pre-cancerous lesions to a tumor that is malignant when cancer begins. Aging persons often have less effective cellular repair systems in addition to the normal risk buildup. Smoking, consuming alcohol, adopting a poor diet, leading a life of inactivity, and air pollution all increase the chance of developing cancer.

Oncology Biosimilars Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Oncology Biosimilars market is estimated to grow annually at a CAGR of around 10.67% over the forecast period (2023-2030)
  • The Oncology Biosimilars industry is projected to grow at a significant rate due to the growing prevalence of cancer
  • Based on drug class segmentation, G-CSF was predicted to show maximum market share in the year 2022
  • Based on type of cancer, breast cancer was the leading type in 2022
  • Based on distribution channel segmentation, hospital retail was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Oncology Biosimilars Market- Segmentation Analysis:

  • The Global Oncology Biosimilars Market is segmented on the basis of Drug Class, Type of Cancer, Distribution Channel, and Region.
  • The market is divided into categories based on Drug Class: monoclonal antibodies, G-CSF, hematopoietic agents, and others. The higher market share of G-CSF is a result of the widespread use of G-CSF after chemotherapy to aid in the recovery of white blood cells following cancer treatment. Granulocyte colony-stimulating factors (G-CSF) are available in a variety of forms, including filgrastim, lenograstim, long-acting filgrastim, and pegfilgrastim.
  • The market is divided into categories based on type of cancer: breast cancer, lung cancer, stomach cancer, prostate cancer, cervical cancer, blood cancer, brain cancer, and others. Due to the highest percentage of breast cancer cases globally among all malignancies, the breast cancer sector commands the market. The risk of breast cancer is increased by a number of variables, including age, obesity, alcoholism, cigarette use, postmenopausal hormone treatment, exposure to radiation history, and family history of the disease.

Oncology Biosimilars Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The Asia Pacific region is a developing market, with Korea, China, and India, in particular, making strides with cancer biosimilars. Due to a large population, rising health consciousness, rising healthcare expenditure, and decreased manufacturing costs, they also reflect the market's future potential.

Oncology Biosimilars Market- Competitive Landscape:

Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, Distribution Channel, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, May 2022, Abevmy (bevacizumab), the third cancer biosimilar produced by Biocon Biologics and Viatris, has made accessible in Canada.

Recent Developments:

September 2022, Celltrion USA received FDA permission for using its oncology biosimilar vegzelma (bevacizumab-add) to treat six different forms of cancer.

Key features of the study:

  • This proposed research study on Oncology Biosimilars market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Oncology Biosimilars market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Oncology Biosimilars market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Oncology Biosimilars market
  • Impact of COVID-19 on Oncology Biosimilars market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Oncology Biosimilars market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Oncology Biosimilars market, we have also included competitive landscape and key innovator analysis for the Oncology Biosimilars market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Oncology Biosimilars market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Oncology Biosimilars market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ONCOLOGY BIOSIMILARS MARKET KEY PLAYERS

  • Teva Pharmaceuticals
  • STADA Arzneimittel AG
  • Shanghai Henlius Biotech
  • Sandoz (Novartis)
  • Samsung Bioepis
  • Pfizer
  • Pfenex Inc.
  • Mylan
  • Innovent Biologics
  • Dr. Reddy's Laboratories
  • Celltrion Healthcare
  • Biocon
  • Apotex
  • Amgen
  • Accord Healthcare

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG CLASS

  • Monoclonal Antibodies
  • G-CSF
  • Hematopoietic Agents
  • Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY TYPE OF CANCER

  • Breast Cancer
  • Lung Cancer
  • Stomach Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Blood Cancer
  • Brain Cancer
  • Others

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Oncology Biosimilars Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Oncology Biosimilars Market Snippet by Drug Class
    • 2.1.2. Oncology Biosimilars Market Snippet by Type of Cancer
    • 2.1.3. Oncology Biosimilars Market Snippet by Distribution Channel
    • 2.1.4. Oncology Biosimilars Market Snippet by Country
    • 2.1.5. Oncology Biosimilars Market Snippet by Region
  • 2.2. Competitive Insights

3. Oncology Biosimilars Key Market Trends

  • 3.1. Oncology Biosimilars Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Oncology Biosimilars Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Oncology Biosimilars Market Opportunities
  • 3.4. Oncology Biosimilars Market Future Trends

4. Oncology Biosimilars Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Oncology Biosimilars Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Oncology Biosimilars Market Landscape

  • 6.1. Oncology Biosimilars Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Oncology Biosimilars Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Monoclonal Antibodies
    • 7.1.3. G-CSF
    • 7.1.4. Hematopoietic Agents
    • 7.1.5. Others

8. Oncology Biosimilars Market - By Type of Cancer

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type of Cancer, 2022 & 2030 (%)
    • 8.1.2. Breast Cancer
    • 8.1.3. Lung Cancer
    • 8.1.4. Stomach Cancer
    • 8.1.5. Prostate Cancer
    • 8.1.6. Cervical Cancer
    • 8.1.7. Blood Cancer
    • 8.1.8. Brain Cancer
    • 8.1.9. Others

9. Oncology Biosimilars Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Online Pharmacies

10. Oncology Biosimilars Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Oncology Biosimilars Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Oncology Biosimilars Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Oncology Biosimilars Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Oncology Biosimilars Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Oncology Biosimilars Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Cancer, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Oncology Biosimilars Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Teva Pharmaceuticals
    • 11.2.2. STADA Arzneimittel AG
    • 11.2.3. Shanghai Henlius Biotech
    • 11.2.4. Sandoz (Novartis)
    • 11.2.5. Samsung Bioepis
    • 11.2.6. Pfizer
    • 11.2.7. Pfenex Inc.
    • 11.2.8. Mylan
    • 11.2.9. Innovent Biologics
    • 11.2.10. Dr. Reddy's Laboratories
    • 11.2.11. Celltrion Healthcare
    • 11.2.12. Biocon
    • 11.2.13. Apotex
    • 11.2.14. Amgen
    • 11.2.15. Accord Healthcare

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us